Eurofins successfully places EUR 300m inaugural Euro bond
Tuesday, November 19, 2013
Eurofins Scientific, the global leader in bioanalytical testing, announces that it has successfully raised EUR 300m in its inaugural Euro bond issuance. The bonds have a five-year maturity, and pay an annual interest rate of 3.125%. The issue was more than three times over-subscribed.
Eurofins intends to use the proceeds of the offering for general corporate purposes, including the funding of acquisitions and expansion investments as part of its objective to double revenues to EUR 2bn by 2017.
Comment from Dr. Gilles Martin, Eurofins CEO:"I am pleased with the success of our inaugural bond issue, and the confidence that investors put into Eurofins. Whilst we have decided to exploit the current favourable interest rates in the market, and secure and diversify long-term funding, we intend to maintain our disciplined approach to acquisitions and a strong balance sheet."
HSBC acted as global coordinator and joint bookrunner for the transaction, with BNP Paribas, SG CIB and UniCredit Bank as joint bookrunners.
The bonds are listed on the regulated market of the Luxembourg stock exchange. The bonds are not registered under the US Securities Act of 1933 as amended (the "Securities Act"), and may not be offered or sold in the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration.
For more information, please visit www.eurofins.com or contact:
Eurofins Investor Relations
Phone: +32 2 766 1620
Notes for the editor:
Eurofins - a global leader in bio-analysis
Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services.
With 15,000 staff in more than 190 laboratories across 37 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.